These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 12181832)

  • 1. [Experience with high-dose immunosuppressive therapy followed by transplantation of autologous stem hematopoietic cells in patients with multiple sclerosis].
    Rossiev VA; Makarov SV; Aleksandrova IIa; Dolgikh GT; Lipshina SR; Stukalova TA; Trushina OA; Fedorova EIu; Lipina LN; Sivak VF; Korenev PP; Murashov BF
    Ter Arkh; 2002; 74(7):35-8. PubMed ID: 12181832
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High-dose immunosuppressive therapy with autologous hematopoietic stem cell transplantation as a treatment option in multiple sclerosis.
    Shevchenko YL; Novik AA; Kuznetsov AN; Afanasiev BV; Lisukov IA; Kozlov VA; Rykavicin OA; Ionova TI; Melnichenko VY; Fedorenko DA; Kulagin AD; Shamanski SV; Ivanov RA; Gorodokin G
    Exp Hematol; 2008 Aug; 36(8):922-8. PubMed ID: 18468768
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hematopoietic stem cell transplantation for multiple sclerosis. A retrospective multicenter study.
    Fassas A; Passweg JR; Anagnostopoulos A; Kazis A; Kozak T; Havrdova E; Carreras E; Graus F; Kashyap A; Openshaw H; Schipperus M; Deconinck E; Mancardi G; Marmont A; Hansz J; Rabusin M; Zuazu Nagore FJ; Besalduch J; Dentamaro T; Fouillard L; Hertenstein B; La Nasa G; Musso M; Papineschi F; Rowe JM; Saccardi R; Steck A; Kappos L; Gratwohl A; Tyndall A; Samijn J;
    J Neurol; 2002 Aug; 249(8):1088-97. PubMed ID: 12195460
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CD34+ selected autologous peripheral blood stem cell transplantation for multiple sclerosis: report of toxicity and treatment results at one year of follow-up in 15 patients.
    Carreras E; Saiz A; Marín P; Martínez C; Rovira M; Villamor N; Aymerich M; Lozano M; Fernández-Avilés F; Urbano-Izpizua A; Montserrat E; Graus F
    Haematologica; 2003 Mar; 88(3):306-14. PubMed ID: 12651270
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Use of Mabtera (rituximab) in treating patients with refractory courses of B-cell lymphoma, along with high-dose chemotherapy and autologous transplantation of hematopoietic stem cells].
    Ptushkin VV; Chimishkian KL; Zhukov NV; Osmanov DSh; Andreeva LIu; Tupitsyn NN; Larionova VB; Mkheidze DM; Poddubnaia NV
    Ter Arkh; 2003; 75(1):65-8. PubMed ID: 12652962
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Autologous stem-cell transplantation in malignant multiple sclerosis: a case with a favorable long-term outcome.
    Kimiskidis V; Sakellari I; Tsimourtou V; Kapina V; Papagiannopoulos S; Kazis D; Vlaikidis N; Anagnostopoulos A; Fassas A
    Mult Scler; 2008 Mar; 14(2):278-83. PubMed ID: 17942513
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical outcomes after autologous haematopoietic stem cell transplantation in patients with progressive multiple sclerosis.
    Xu J; Ji BX; Su L; Dong HQ; Sun XJ; Liu CY
    Chin Med J (Engl); 2006 Nov; 119(22):1851-5. PubMed ID: 17134581
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Use of high dose chemotherapy with autologous peripheral hemopoietic cell transplantation in multiple sclerosis].
    Kliuzhev VM; Kovalenko PA; Rukavitsyn OA; Shamanskiĭ SV; Baziĭ NI; Ian'shina IL
    Voen Med Zh; 2002 Aug; 323(8):41-3. PubMed ID: 12379029
    [No Abstract]   [Full Text] [Related]  

  • 9. [The role and place of high-dose immunosuppressive therapy and autologous transplantation of hematopoietic stem cells for autoimmune diseases].
    Makarov SV; Rossiev VA; Mishchenko OV; Kozlov VA; Semagina OV; Alexandrova IY; Grishina GV; Minaev YL
    Ter Arkh; 2016; 88(1):53-59. PubMed ID: 26978610
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Randomized comparison of granulocyte colony-stimulating factor versus granulocyte-macrophage colony-stimulating factor plus intensive chemotherapy for peripheral blood stem cell mobilization and autologous transplantation in multiple myeloma.
    Arora M; Burns LJ; Barker JN; Miller JS; Defor TE; Olujohungbe AB; Weisdorf DJ
    Biol Blood Marrow Transplant; 2004 Jun; 10(6):395-404. PubMed ID: 15148493
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High dose chemotherapy followed by autologous haemopoietic stem cell transplant in multiple myeloma.
    Kumar L; Raju GM; Ganessan K; Shawgi S; Menon H; Wadhwa J; Sharma A; Singh R; Kochupillai V
    Natl Med J India; 2003; 16(1):16-21. PubMed ID: 12715951
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Early highly aggressive MS successfully treated by hematopoietic stem cell transplantation.
    Fagius J; Lundgren J; Oberg G
    Mult Scler; 2009 Feb; 15(2):229-37. PubMed ID: 18805841
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Clinical outcome 6 years after autologous hematopoietic stem cell transplantation in multiple sclerosis].
    Saiz A; Blanco Y; Berenguer J; Gómez-Choco M; Carreras E; Arbizu T; Graus F
    Neurologia; 2008 Sep; 23(7):405-7. PubMed ID: 18726717
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Autologous hemopoietic stem cell transplantation for multiple sclerosis: is it worthwile?
    Fassas A; Mancardi GL
    Autoimmunity; 2008 Dec; 41(8):601-10. PubMed ID: 18958762
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunological reconstitution after autologous hematopoietic stem cell transplantation in patients with systemic sclerosis: relationship between clinical benefits and intensity of immunosuppression.
    Bohgaki T; Atsumi T; Bohgaki M; Furusaki A; Kondo M; Sato-Matsumura KC; Abe R; Kataoka H; Horita T; Yasuda S; Amasaki Y; Nishio M; Sawada K; Shimizu H; Koike T
    J Rheumatol; 2009 Jun; 36(6):1240-8. PubMed ID: 19447934
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sequential intensified conditioning and tapering of prophylactic immunosuppressants for graft-versus-host disease in allogeneic hematopoietic stem cell transplantation for refractory leukemia.
    Liu QF; Fan ZP; Zhang Y; Jiang ZJ; Wang CY; Xu D; Sun J; Xiao Y; Tan H
    Biol Blood Marrow Transplant; 2009 Nov; 15(11):1376-85. PubMed ID: 19822296
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dose modification protocol using intravenous busulfan (Busulfex) and cyclophosphamide followed by autologous or allogeneic peripheral blood stem cell transplantation in patients with hematologic malignancies.
    Williams CB; Day SD; Reed MD; Copelan EA; Bechtel T; Leather HL; Wingard JR; Abbott BL; Abhyankar S; McGuirk JP
    Biol Blood Marrow Transplant; 2004 Sep; 10(9):614-23. PubMed ID: 15319773
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Maintenance therapy with thalidomide improves overall survival after autologous hematopoietic progenitor cell transplantation for multiple myeloma.
    Brinker BT; Waller EK; Leong T; Heffner LT; Redei I; Langston AA; Lonial S
    Cancer; 2006 May; 106(10):2171-80. PubMed ID: 16598756
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intense immunosuppression followed by autologous stem cell transplantation in severe multiple sclerosis.
    Capello E; Saccardi R; Murialdo A; Gualandi F; Pagliai F; Bacigalupo A; Marmont A; Uccelli A; Inglese M; Bruzzi P; Sormani MP; Cocco E; Meucci G; Massacesi L; Bertolotto A; Lugaresi A; Merelli E; Solari A; Filippi M; Mancardi GL;
    Neurol Sci; 2005 Dec; 26 Suppl 4():S200-3. PubMed ID: 16388358
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical and quality of life responses to high-dose chemotherapy plus autologous stem cell transplantation in patients with multiple sclerosis: two case reports.
    Novik AA; Ionova TI; Bisaga GN; Kishtovich AV; Fedorenko DA; Ivanov RA; Gorodokin GI
    Cytotherapy; 2005; 7(4):363-7. PubMed ID: 16162458
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.